Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol vs Ondansetron for Cannabis Hyperemesis Syndrome
NCT03056482Phase 4Completed
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of haloperidol in cannabinoid hyperemesis syndrome (CHS). Started May 2017; status: completed.
02
Drugs
haloperidol
03
Conditions
cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on NCT03056482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056482.